表紙
市場調查報告書

市場聚光燈:骨髓纖維化(MF)

Market Spotlight: Myelofibrosis (MF)

出版商 Datamonitor Healthcare 商品編碼 955895
出版日期 內容資訊 英文 41 Pages
商品交期: 最快1-2個工作天內
價格
市場聚光燈:骨髓纖維化(MF) Market Spotlight: Myelofibrosis (MF)
出版日期: 2020年08月14日內容資訊: 英文 41 Pages
簡介

本報告提供全球骨髓纖維化 (MF) 的治療藥臨床實驗形勢和市場趨勢預測相關分析,疾病概要和流行病學的預測,目前主要治療藥 (已上市/開發中產品) 和臨床實驗的進展,目前未滿足需求和未來的市場機會,臨床實驗/市場將來相關專家的見解等資訊彙整,為您概述為以下內容。

目錄

概要

重要的要點

疾病的背景情況

治療方法

  • 貧血
  • 治癒的治療

流行病學

成藥

開發平台藥物

最近的活動和分析師的意見

  • 骨髓纖維化用Momelotinib(2020年5月6日)
  • 骨髓纖維化用Reblozyl(2019年11月6日)
  • 骨髓纖維化用Pracinostat(2019年7月31日)
  • 骨髓纖維化用CPI-0610(2019年6月3日)
  • 骨髓纖維化用Inrebic(2019年6月3日)

今後主要的活動

法規上主要的動向

  • Inrebic批准可促進骨髓纖維化和Celgene的買家Bristol

成功的概率

授權合約/資產收購交易

商機

臨床實驗形勢

  • 臨床試驗贊助者的分類:各狀況
  • 臨床試驗贊助者的分類:各相位

參考文件

  • 處方藥的資訊

附錄

目錄
Product Code: DMKC0179494

Myelofibrosis is a myeloproliferative neoplasm which can exist as a primary disease known as primary myelofibrosis, or can evolve to post-polycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis from PV or ET. It is characterized by the buildup of scar tissue (fibrosis) in bone marrow, which leads to a reduction in blood cell production.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.

Bristol Myers Squibb's Inrebic and Incyte's Jakafi are the only marketed drugs for myelofibrosis. These drugs are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for myelofibrosis are in Phase II. Therapies in development for myelofibrosis focus on a wide variety of targets. The majority of the pipeline drugs are administered via the oral route.

High-impact upcoming events for drugs in the myelofibrosis space comprise topline Phase III trial results for pacritinib, Reblozyl, momelotinib, and Imetelstat, and an estimated NDA filing for pacritinib.

The overall likelihood of approval of a Phase I hematologic asset is 9.9%, and the average probability a drug advances from Phase III is 61.4%. Drugs, on average, take 9.1 years from Phase I to approval, compared to 9.4 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for myelofibrosis have been in the early and mid-phases of development, with 86% of trials in Phase I-II, and only 14% in Phase III-IV.

The US has a substantial lead in the number of myelofibrosis clinical trials globally. Germany leads the major European markets, while Israel has the top spot in Asia.

Novartis has the highest number of completed clinical trials for myelofibrosis, with 14 trials.

Novartis leads industry sponsors with the highest overall number of clinical trials for myelofibrosis, followed by Incyte.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Anemia
  • Curative treatment

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Momelotinib for Myelofibrosis (May 6, 2020)
  • Reblozyl for Myelofibrosis (November 6, 2019)
  • Pracinostat for Myelofibrosis (July 31, 2019)
  • CPI-0610 for Myelofibrosis (June 3, 2019)
  • Inrebic for Myelofibrosis (June 3, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Inrebic Approval Is A Boost For Myelofibrosis And Celgene's Buyer Bristol

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Roche Paying $390m Up Front For Fibrosis-Fighting Promedior

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of myelofibrosis, 2019-28
  • Figure 2: Overview of pipeline drugs for myelofibrosis in the US
  • Figure 3: Pipeline drugs for myelofibrosis, by company
  • Figure 4: Pipeline drugs for myelofibrosis, by drug type
  • Figure 5: Pipeline drugs for myelofibrosis, by classification
  • Figure 6: Momelotinib for Myelofibrosis (May 6, 2020): Phase III - Simplify 2 (vs Best Available Therapy)
  • Figure 7: Reblozyl for Myelofibrosis (November 6, 2019): Phase II - MF-001
  • Figure 8: CPI-0610 for Myelofibrosis (June 3, 2019): Phase I/II - MANIFEST (+/- Ruxolitinib)
  • Figure 9: Key upcoming events in myelofibrosis
  • Figure 10: Probability of success in the myelofibrosis pipeline
  • Figure 11: Clinical trials in myelofibrosis
  • Figure 12: Top 10 drugs for clinical trials in myelofibrosis
  • Figure 13: Top 10 companies for clinical trials in myelofibrosis
  • Figure 14: Trial locations in myelofibrosis
  • Figure 15: Myelofibrosis trials status
  • Figure 16: Myelofibrosis trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of myelofibrosis, 2019-28
  • Table 2: Marketed drugs for myelofibrosis
  • Table 3: Pipeline drugs for myelofibrosis in the US
  • Table 4: Momelotinib for Myelofibrosis (May 6, 2020)
  • Table 5: Reblozyl for Myelofibrosis (November 6, 2019)
  • Table 6: Pracinostat for Myelofibrosis (July 31, 2019)
  • Table 7: CPI-0610 for Myelofibrosis (June 3, 2019)
  • Table 8: Inrebic for Myelofibrosis (June 3, 2019)
  • Table 9: Historical global sales, by drug ($m), 2015-19
  • Table 10: Forecasted global sales, by drug ($m), 2020-24